CAP1

Across TCGA pan-cancer cohorts, CAP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CAP1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CAP1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CAP1 expression acts as an unfavorable survival marker.

GBM, LUAD, and PDAC are the cancer types where CAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.246	0.549	<.001	21	view →
LUAD	DFS	Quartile	II,III,IV	0.587	0.989	.008	12	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
CCRCC	OS	Median	All	0.909	1.000	.019	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CAP1–GBM (OS)

Open the GBM breakdown →